Breckenridge 11月16日召回一批次普萘洛尔缓释胶囊:60毫克100粒装,可能含金属污染

Breckenridge Pharmaceutical, Inc. 2026年11月16日在新泽西州 Berkeley Heights 宣布,自愿在消费者层面召回一个批次的盐酸普萘洛尔缓释胶囊(USP 60毫克),原因是可能存在金属污染。该召回在美国食品药品管理局(FDA)知悉下进行。
涉事产品为100粒瓶装,NDC为51991-817-01,批次号PK25110035,有效期至2029年5月。胶囊由 Adare Pharma Solutions 生产。
该批次产品于2026年10月26日至11月4日分销至全美的批发商与药房。公司公告列出了负责召回服务的 Qualanex 的联系方式,消费者可在美东时间周一至周五上午9时至下午5时联系处理。
使用该产品后出现不良反应或质量问题,可向 FDA 的 MedWatch 不良事件报告计划报告。公告未提及已收到的患病或伤害报告数量。
图中是普萘洛尔药片,本次召回的正是盐酸普萘洛尔缓释胶囊
Breckenridge Recalls One Lot of Propranolol Extended-Release Capsules on November 16: 60 mg, 100-Count, Over Potential Metal Contamination
Breckenridge Pharmaceutical, Inc. announced on November 16, 2026, in Berkeley Heights, New Jersey, that it is voluntarily recalling to the consumer level one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, due to potential metal contamination. The capsules were manufactured by Adare Pharma Solutions, and the recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
The affected product is a 100-count bottle with NDC 51991-817-01, lot PK25110035, and an expiration date of May 2029.
Product from the lot was distributed nationwide to wholesalers and pharmacies between October 26, 2026 and November 4, 2026. The announcement gives contact details for Qualanex, the company's designated recall service provider, available Monday through Friday, 9 a.m. to 5 p.m. Eastern Time.
Adverse reactions or quality problems experienced with the use of the product may be reported to the FDA's MedWatch Adverse Event Reporting program. The announcement did not state a number of reported illnesses or injuries.
发布:GSM·美国(发布链接)
图片来源:Wikimedia Commons, Sarang, Public domain
GSM Global · 本篇英文版 English edition of this story

